Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced the launch of its brain health supplement, RecalMax™, in the U.S. An estimated 12 million people suffer from neurodegenerative diseases such as Alzheimer’s, for which the use of RecalMax™ may help, in the U.S., Europe, and Japan. That represents an estimated market of more than $3 billion per year.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160830005164/en/
RecalMax™ Promotes Healthy Brain Function (Photo: Business Wire)
The product will be available through www.recalmax.com and in over 1,000 newspapers and prints in the U.S.
As previously announced, RecalMax™ was tested in the U.S. in a four month human survey use clinical trial in 72 patients with low memory and learning. The patients were given one capsule twice a day for 16 weeks. Their performance on tests and their satisfaction levels were assessed at the beginning of the trial, at the midpoint, and at the end.
The results of RecalMax™ use included:
1. 115% increase in the recall of words and names
2. 49.5% increase in maintaining thoughts when distracted
3. 35% increase in processing speed
The data also showed that RecalMax™ is very well tolerated with no serious adverse events. The only minor events reported were episodes of dry mouth, which were resolved by drinking 62oz of water daily, and sleep disturbances if taken in the late afternoon.
RecalMax™ is a proprietary oral low dose formulation of two important amino acids, L-Citrulline and L-Arginine, along with a natural absorption enhancer called Bioperine®. The body converts L-Arginine to a substance called nitric oxide, which then sends a signal for blood vessels to relax. The result is increased blood flow to the brain, which is expected to improve cognitive functioning.
As the population ages, the market for treatment approaches for all neurodegenerative diseases is expected to grow rapidly, possibly climbing past $20 billion.
“We believe RecalMax™ could generate close to $5 million a year, adding to the revenues already being generated by the success of our Vesele® dietary supplement,” said Innovus CEO Dr. Bassam Damaj. “We are marketing RecalMax™ under our Beyond Human platform, which targets over 1,000 newspapers in the U.S. and more than 1.5 million online subscribers to our websites.”
RecalMax™ is a proprietary, novel oral dietary supplement to maximize nitric oxide’s beneficial effects on brain health. RecalMax™ contains a patented formulation of low dose L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine®. For more information visit www.recalmax.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005164/en/Business Wire
Last updated on: 30/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.